Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Required: KRAS g12d mutation

Must have received: standard therapy (including targeted therapy) appropriate for tumor type and stage

Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage

Cannot have received: KRAS G12D inhibitor

previously treated with an investigational KRAS G12D inhibitor

Cannot have received: pan- or multi-RAS inhibitor

previously treated with...pan- or multi-RAS inhibitor

Cannot have received: direct RAS-targeted therapy (e.g., degraders and inhibitors)

prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)